IBSA Pharma Inc, a company involved in topical treatment of acute pain and the treatment of hypothyroidism, has repurchased marketing and distribution rights for Flector (diclofenac epolamine) topical system 1.3% from United States-based Pfizer, it was reported on Tuesday.
With the reacquisition, IBSA is providing two prescription topical drugs, Flector and Licart, intended to treat acute pain due to minor strains, sprains, and contusions. IBSA says that both the products are produced under its strict Quality System control.
The marketing rights for Flector have reverted to IBSA effective January 2021. The company has taken a decision to reduce the price of Flector and offer significant patient savings programs. Licart is the first and only once-a-day topical nonsteroidal anti-inflammatory drug therapy approved by the FDA.
PureTech receives FDA Fast Track designation for LYT-200 in HR-MDS
MaaT Pharma outlines potential Phase 3 development plan for MaaT013 after CHMP negative opinion
Bayer's Kerendia wins FDA approval for chronic kidney disease associated with type 1 diabetes
Myosin Therapeutics chosen for 2026-2027 NCI Investor Initiatives Showcase
Medtronic receives FDA clearance for LigaSure RAS Maryland instrument on Hugo system
VaxThera partners with Codagenix for next generation yellow fever vaccine advancement
MaaT Pharma receives negative CHMP trend vote for MaaT013
FDA approves Scholar Rock's ISEMBYLD to treat spinal muscular atrophy
FDA grants priority review to Takeda's zasocitinib application for plaque psoriasis
Armata Pharmaceuticals announces receipt of FDA Breakthrough Therapy Designation for AP-SA02
GSK reports positive Jideytro data supporting potential first-line lung cancer use
Eloxx Pharmaceuticals commences Phase 2b study of exaluren
Meant Health announces expansion of telehealth access for FDA-approved GLP-1 prescriptions
US FDA grants orphan drug designation for Lundbeck's asedebart